BioSpace News Archive

Scipher Medicine, a precision immunology company matching patients with most effective therapy, has appointed former United States Surgeon General Regina Benjamin, MD, MBA, to its Board of Advisors.

P ortfolio includes VIP152, a highly selective PTEFb /CDK9 inhibitor with encouraging Phase 1 monotherapy activity , including complete responses in DH-DLBCL Vincera intends to pursue multiple accelerated approval opportunities in M YC - and MCL1- driven cancers Preclinical bioconjugation platform designed to overcome limitations of small - molecule and antibody - drug conjugates use to treat cancer SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE)

Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, and University of Dundee, a top-ranked university in the UK for biological sciences, announced today a research collaboration agreement with the aim to identify and develop a novel class of medicines that target and degrade disease-causing proteins

66.3% of Patients Reported Pain Relief Within Two Hours of Treatment with Rapid Uptake via the Upper Nasal Space Resulting in Onset of Relief as Early as 15 Minutes for Some Patients Data Suggest Use of Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology with DHE May Offer Convenience, Clinical Benefit for Acute Migraine Patients

SkinCeuticals, a leader in advanced skincare technology, announces the launch of a minimally invasive, skin rejuvenation protocol with Vivace® Fractional Micro Needle Radio Frequency Treatment featuring SkinCeuticals C E Ferulic.

Crown Bioscience today announces the appointment of Pam Shang as vice president for global quality. Mrs. Shang will be instrumental in further enhancing global quality across the company, leveraging her deep expertise in implementing quality systems for pharma and biotechnology clients including in GLP, GMP and other regulated environments. This press release features multimedia. View the full release here: https://www.busi

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline Phase 1 clinical trial results of OTX-CSI

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the virtual Joint 49 th Annual Child Neurology Society & 16 th International Child Neurology Society Congress (CNS-ICNA) Meeting. The CNS-ICNA annual meeting is being held virtually from

MilliporeSigma celebrated the topping-out ceremony for its new membrane production plant in Darmstadt, Germany.

Hancock Jaffe Laboratories, Inc. today announced that it has engaged Syntactx LLC to assist Hancock Jaffe with the VenoValve U.S. pivotal trial.